Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NASDAQ:IMVT NYSE:QGEN NASDAQ:SLNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.21-2.6%$48.54$21.72▼$54.60$10.06B1.252.19 million shs2.09 million shsIMVTImmunovant$16.16-3.8%$16.29$12.72▼$32.10$2.93B0.451.46 million shs2.86 million shsQGENQiagen$45.30-1.7%$48.47$37.63▼$51.88$10.24B0.641.32 million shs992,179 shsSLNOSoleno Therapeutics$53.62-5.5%$77.05$41.50▼$90.32$3.01B-2.721.82 million shs3.25 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma0.00%-4.07%+0.06%+28.73%+82.96%IMVTImmunovant0.00%-5.72%+6.32%+3.19%-44.37%QGENQiagen0.00%-4.70%-7.46%-3.77%+1.62%SLNOSoleno Therapeutics0.00%-23.15%-30.69%-32.26%+10.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.21-2.6%$48.54$21.72▼$54.60$10.06B1.252.19 million shs2.09 million shsIMVTImmunovant$16.16-3.8%$16.29$12.72▼$32.10$2.93B0.451.46 million shs2.86 million shsQGENQiagen$45.30-1.7%$48.47$37.63▼$51.88$10.24B0.641.32 million shs992,179 shsSLNOSoleno Therapeutics$53.62-5.5%$77.05$41.50▼$90.32$3.01B-2.721.82 million shs3.25 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma0.00%-4.07%+0.06%+28.73%+82.96%IMVTImmunovant0.00%-5.72%+6.32%+3.19%-44.37%QGENQiagen0.00%-4.70%-7.46%-3.77%+1.62%SLNOSoleno Therapeutics0.00%-23.15%-30.69%-32.26%+10.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$63.9424.86% UpsideIMVTImmunovant 2.83Moderate Buy$33.60107.92% UpsideQGENQiagen 2.27Hold$49.699.68% UpsideSLNOSoleno Therapeutics 3.08Buy$115.09114.64% UpsideCurrent Analyst Ratings BreakdownLatest IMVT, SLNO, QGEN, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $82.009/10/2025SLNOSoleno TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/4/2025IMVTImmunovantHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.009/3/2025BBIOBridgeBio PharmaJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$55.00 ➝ $70.008/29/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.008/27/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$106.008/20/2025SLNOSoleno TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$123.008/18/2025SLNOSoleno TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.00 ➝ $110.008/12/2025IMVTImmunovantJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $37.008/12/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $30.008/11/2025IMVTImmunovantCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$235.81M41.52N/AN/A($7.71) per share-6.64IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AQGENQiagen$2.04B4.94$3.15 per share14.37$16.05 per share2.82SLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)IMVTImmunovant-$413.84M-$2.85N/AN/AN/AN/A-80.99%-72.23%11/6/2025 (Estimated)QGENQiagen$83.59M$1.6926.7618.412.4318.30%14.77%8.87%11/5/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.14N/AN/AN/AN/A-73.74%-56.67%11/5/2025 (Estimated)Latest IMVT, SLNO, QGEN, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2026IMVTImmunovant-$0.69-$0.60+$0.09-$0.71N/AN/A8/6/2025Q2 2025SLNOSoleno Therapeutics-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 million8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million8/5/2025Q2 2025QGENQiagen$0.60$0.60N/A$0.44$523.97 million$533.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AQGENQiagen$0.250.55%N/A14.79%N/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A5.195.08IMVTImmunovantN/A12.3212.32QGENQiagen0.251.611.35SLNOSoleno Therapeutics0.2115.1315.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%IMVTImmunovant47.08%QGENQiagen70.00%SLNOSoleno Therapeutics97.42%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%IMVTImmunovant1.80%QGENQiagen9.00%SLNOSoleno Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400191.17 million156.38 millionOptionableIMVTImmunovant120174.32 million171.18 millionOptionableQGENQiagen5,765222.29 million202.29 millionOptionableSLNOSoleno Therapeutics3053.15 million49.74 millionOptionableIMVT, SLNO, QGEN, and BBIO HeadlinesRecent News About These CompaniesWhat is Lifesci Capital's Estimate for SLNO Q3 Earnings?September 14 at 6:34 AM | marketbeat.comSLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 13 at 3:15 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc.- SLNOSeptember 13 at 2:45 PM | prnewswire.comSoleno Therapeutics (NASDAQ:SLNO) Upgraded to Strong-Buy at Lifesci CapitalSeptember 13 at 7:21 AM | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Trading Down 8.9% - What's Next?September 12 at 3:13 PM | marketbeat.comRosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNOSeptember 12 at 3:00 PM | prnewswire.comOptimize Financial Inc Makes New Investment in Soleno Therapeutics, Inc. $SLNOSeptember 12 at 6:41 AM | marketbeat.comWoodline Partners LP Grows Stock Position in Soleno Therapeutics, Inc. $SLNOSeptember 12 at 6:41 AM | marketbeat.comFred Alger Management LLC Has $2.89 Million Holdings in Soleno Therapeutics, Inc. $SLNOSeptember 12 at 5:19 AM | marketbeat.comSOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the FirmSeptember 11 at 5:06 PM | globenewswire.comSoleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens BermanSeptember 11 at 2:29 PM | globenewswire.comAre Legal Probes Shaping Trust in Soleno Therapeutics’ (SLNO) Drug Pipeline and Investor Relations?September 11 at 11:55 AM | finance.yahoo.comSoleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerSeptember 11 at 10:36 AM | zacks.comSoleno Therapeutics (SLNO) Falls Hard on Patient DeathSeptember 11 at 6:54 AM | msn.comSoleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs MuraSeptember 10, 2025 | businesswire.comSLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law FirmSeptember 10, 2025 | businesswire.comSoleno Therapeutics stock falls after patient death reportSeptember 10, 2025 | in.investing.comUnpacking the Latest Options Trading Trends in Soleno TherapeuticsSeptember 10, 2025 | benzinga.comSoleno drops on death of patient treated with Vykat XRSeptember 10, 2025 | msn.comSoleno Therapeutics Stock Tanks After Patient Treated With Drug Dies – More Details InsideSeptember 10, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNOSeptember 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMVT, SLNO, QGEN, and BBIO Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$51.21 -1.39 (-2.64%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$52.71 +1.50 (+2.93%) As of 09/12/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Immunovant NASDAQ:IMVT$16.16 -0.64 (-3.81%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$16.28 +0.13 (+0.77%) As of 09/12/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Qiagen NYSE:QGEN$45.30 -0.76 (-1.65%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$45.29 -0.01 (-0.02%) As of 09/12/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Soleno Therapeutics NASDAQ:SLNO$53.62 -3.10 (-5.47%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$53.06 -0.56 (-1.04%) As of 09/12/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
